Who qualifies for GLP-1 weight management online?

In short: Increase Health's GLP-1 weight management program is for adults 18 and over in a state our provider network covers, usually with a BMI of 30 or more, or 27 or more with a weight-related health condition. A licensed provider reviews your intake and decides. If you're not approved, you're not charged. The questionnaire is the next step.

Who qualifies for GLP-1 weight management treatment online?

To be considered, you need to be 18 or older, live in a state the network covers, and usually have a BMI of 30 or more, or 27 or more with a weight-related condition. You can't have a personal or family history of medullary thyroid cancer or MEN 2, and you can't be pregnant or breastfeeding.

Meeting those points means a provider will review your intake, not that you'll be prescribed. The provider weighs your whole health history and medicines, and prescribes only if treatment is appropriate for you.

Increase Health's providers prescribe compounded semaglutide and compounded tirzepatide. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality¹⁰. The safety facts on this page come from the FDA labels and trials of the approved medicines, Wegovy and Zepbound¹².

Where do the BMI 30 and 27 numbers come from?

They come from the trials behind the FDA-approved medicines. The main Wegovy and Zepbound trials (STEP 1 and SURMOUNT-1, both in the New England Journal of Medicine) enrolled adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition¹²³⁴. The labels describe this as obesity, or overweight with a weight-related condition. Prescribers use the same lines.

Weight-related conditions in those trials included high blood pressure, high cholesterol, obstructive sleep apnea and cardiovascular disease.

So if your BMI is between 27 and 30 with no weight-related condition, or under 27, a provider will usually say this treatment isn't right for you now. These medicines were studied as long-term treatment for excess weight that affects health, not for a few pounds before an event.

What does the intake ask, and why?

Every question maps to something in the labels or to a safety judgment the provider has to make. Answer honestly and completely. A question you skip or soften is a risk the provider can't see. You'll be asked to confirm that your answers are accurate before you submit.

Your care team will also want to know about any upcoming surgery or sedation, and, if you have type 2 diabetes, any diabetic eye disease, because both labels carry warnings about them¹².

Can I take a GLP-1 if I'm pregnant, breastfeeding or planning a pregnancy?

No. Increase Health doesn't treat anyone who is pregnant, breastfeeding or planning a pregnancy. The Wegovy and Zepbound labels say weight reduction offers no benefit in pregnancy and may harm the baby, so the medicine should be stopped once a pregnancy is recognized¹². Wegovy's label adds a planning step.

• Planning a pregnancy: the Wegovy label says to stop "at least 2 months before a planned pregnancy because of the long half-life of semaglutide", meaning it stays in the body a long time¹. Tell your care team about your plans before you start, not after.
• Birth control pills: the Zepbound label warns that tirzepatide may make birth control pills less effective, especially in the first weeks and after each dose increase. It suggests switching to a non-pill method, or adding a barrier method, during those times². Tell your care team which method you use.
• If you become pregnant during treatment: stop and contact your care team and your own doctor.

Does a history of thyroid cancer rule me out?

A personal or family history of medullary thyroid carcinoma (MTC), or a personal history of MEN 2, rules these medicines out. That's a contraindication on both FDA labels¹². It comes from a boxed warning: these medicines caused thyroid C-cell tumors in rodents. Whether that happens in people isn't known¹².

MTC is one specific type of thyroid cancer. Other thyroid cancers and thyroid conditions are different, but your care team still needs your full history and may ask for records. If you're being treated for any cancer now, start the conversation with your cancer care team.

Why might a provider say no?

The most common reasons are a BMI below the range, a label contraindication, pregnancy or pregnancy plans, or a condition that needs in-person care first. Some are firm label lines. Others are the provider's judgment about whether online treatment is safe for you. A "no" is a medical decision, not a verdict on you.

What happens if I'm not approved?

You're not charged. Your card is authorized at checkout and charged only if a provider approves your prescription. If the provider decides treatment isn't right for you, you pay $0, and nothing renews because there's no subscription. Often the next step is a conversation with your own doctor.

If you are approved, one payment covers 3 months, your medication ships to your door, and you can message your care team. Klarna's 4 interest-free payments are available at checkout.

What people often get wrong

• "If my BMI qualifies, I'll be approved." BMI is only the starting point. Providers also decline for thyroid cancer history, past serious allergy, severe gastroparesis, pregnancy or pregnancy plans, and, as a matter of judgment, past pancreatitis or an active eating disorder¹²⁶⁹.
• "Leaving something off the intake is harmless." The questions follow the label warnings. A provider can't protect you from a risk they don't know about, and a skipped answer can lead to a prescription that isn't safe for you.
• "Pregnancy is the only timing that matters." The Wegovy label says to stop at least 2 months before a planned pregnancy, so plans matter as much as a current pregnancy¹.
• "Birth control works the same." The Zepbound label warns that birth control pills may work less well, especially in the first weeks and after dose increases².
• "GLP-1s carry a suicide warning, so any mental health history rules me out." FDA removed that warning in January 2026 after a review of 91 trials found no increased risk⁵. Your care team and its licensed providers will still ask about mood, mental health and eating, and decide case by case.